Kintscher Ulrich, Lyon Christopher, Wakino Shu, Bruemmer Dennis, Feng Xu, Goetze Stephan, Graf Kristof, Moustakas Aristidis, Staels Bart, Fleck Eckart, Hsueh Willa A, Law Ronald E
Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, University of California, Los Angeles, School of Medicine, Los Angeles, Calif 90095, USA.
Circ Res. 2002 Nov 29;91(11):e35-44. doi: 10.1161/01.res.0000046017.96083.34.
Integrins play an important role in vascular smooth muscle cell (VSMC) migration, a crucial event in the development of restenosis and atherosclerosis. Transforming growth factor-beta (TGF-beta) is highly expressed in restenotic and atherosclerotic lesions, and known to induce integrin expression. Peroxisome proliferator-activated receptor alpha (PPARalpha), a member of the nuclear receptor superfamily, regulates gene expression in a variety of vascular cells. We investigated the effects of PPARalpha ligands on TGF-beta-induced beta3 and beta5 integrin expression and potential interaction between PPARalpha and TGF-beta signaling. PPARalpha ligands WY-14643 (100 micromol/L) and 5,8,11,14-eicosatetranoic acid (ETYA, 50 micromol/L) inhibited TGF-beta-induced beta5 integrin protein expression by 72+/-6.8% and 73+/-7.1%, respectively (both P<0.05). TGF-beta-stimulated beta3 integrin expression was not affected by PPARalpha ligands. Both PPARalpha ligands also suppressed TGF-beta-induced beta5 integrin mRNA levels. PPARalpha ligands inhibited TGF-beta-inducible transcription of beta5 integrin by an interaction with a TGF-beta response element between nucleotides -63 and -44, which contains a Sp1/Sp3 transcription factor binding site. Nuclear complexes binding to the TGF-beta response region contained Sp1/Sp3 and TGF-beta-regulated Smad 2, 3, and 4 transcription factors. TGF-beta-stimulated Sp1/Smad4 nuclear complex formation was inhibited by WY-14643 and ETYA with a parallel induction of PPARalpha/Smad4 interactions. However, in vitro pull-down experiments failed to demonstrate direct binding between PPARalpha/Smad4. Both PPARalpha ligands blocked PDGF-directed migration of TGF-beta-pretreated VSMCs, a process mediated, in part, by beta5 integrins. The present study demonstrates that PPARalpha activators inhibit TGF-beta-induced beta5 integrin transcription in VSMCs through a novel indirect interaction between ligand-activated PPARalpha and the TGF-beta-regulated Smad4 transcription factors. The full text of this article is available at http://www.circresaha.org.
整合素在血管平滑肌细胞(VSMC)迁移中起重要作用,而VSMC迁移是再狭窄和动脉粥样硬化发展过程中的关键事件。转化生长因子-β(TGF-β)在再狭窄和动脉粥样硬化病变中高表达,且已知可诱导整合素表达。过氧化物酶体增殖物激活受体α(PPARα)是核受体超家族的成员,可调节多种血管细胞中的基因表达。我们研究了PPARα配体对TGF-β诱导的β3和β5整合素表达的影响以及PPARα与TGF-β信号之间的潜在相互作用。PPARα配体WY-14643(100 μmol/L)和5,8,11,14-二十碳四烯酸(ETYA,50 μmol/L)分别将TGF-β诱导的β5整合素蛋白表达抑制了72±6.8%和73±7.1%(均P<0.05)。TGF-β刺激的β3整合素表达不受PPARα配体影响。两种PPARα配体也抑制了TGF-β诱导的β5整合素mRNA水平。PPARα配体通过与核苷酸-63至-44之间的TGF-β反应元件相互作用,抑制TGF-β诱导的β5整合素转录,该元件包含一个Sp1/Sp3转录因子结合位点。与TGF-β反应区域结合的核复合物包含Sp1/Sp3以及TGF-β调节的Smad 2、3和4转录因子。WY-14643和ETYA抑制了TGF-β刺激的Sp1/Smad4核复合物形成,同时平行诱导了PPARα/Smad4相互作用。然而,体外下拉实验未能证明PPARα/Smad4之间的直接结合。两种PPARα配体均阻断了血小板衍生生长因子(PDGF)引导的TGF-β预处理的VSMC迁移,这一过程部分由β5整合素介导。本研究表明,PPARα激活剂通过配体激活的PPARα与TGF-β调节的Smad4转录因子之间的新型间接相互作用,抑制VSMC中TGF-β诱导的β5整合素转录。本文全文可在http://www.circresaha.org获取。